The KEAP1/Nrf2 axis plays a major role in regulating cellular redox balance and is a prime therapeutic target for cancer and different chronic diseases, such as neurodegenerative diseases or NASH [76]; in fact, Nrf2 activity correlates with the grade of inflammation in liver samples from patients with NAFLD/NASH with different degrees of steatosis, fibrosis and inflammation (portal and lobular) including a pediatric cohort [77]. The gene discussed is KEAP1; the disease is metabolic dysfunction-associated steatohepatitis.